CStone and Kimia Therapeutics Partner to Advance Potential First-in-Class DNA Damage Response Therapy for Solid Tumors in China and Australia
CStone Pharmaceuticals and Kimia Therapeutics launch a clinical collaboration to advance a potential first-in-class DNA damage response (DDR) asset for sol
Research Desk
Suzhou, China–based CStone Pharmaceuticals (HKEX: 2616) announced on November 4, 2026, that it has entered into a clinical collaboration agreement with Kimia Therapeutics, Inc., a Berkeley, California–based biopharmaceutical company developing innovative therapeutics for oncology and immunology.
Collaboration Announced to Advance Novel DDR-Targeting Asset
The agreement is aimed at advancing the clinical development of a potential first-in-class asset targeting the DNA damage response (DDR) pathway, which is described as critical for solid tumor cell survival. Under the collaboration, CStone will lead the clinical development of the asset in mainland China and Australia.
The companies stated that the collaboration reflects international recognition of CStone's clinical development and regulatory expertise and supports the company's strategy of disciplined external innovation and global expansion.
It also creates a pathway for CStone to participate in the global commercial value of a first-in-class asset through milestone payments and royalties.
Division of Responsibilities Under a Co-Development Model
Under the terms of the agreement, CStone will lead the Phase I clinical development of the asset in mainland China and Australia, applying what the company describes as its full-spectrum oncology clinical development and regulatory capabilities.
Kimia will contribute the clinical supply of the asset, along with scientific guidance, product-related regulatory oversight, and other agreed-upon development support. The arrangement is characterized by the companies as a co-development model built on each party's complementary strengths.
Kimia will reimburse CStone for the applicable clinical development costs. CStone is eligible to receive milestone payments plus royalties on global net sales of the asset during the applicable royalty term, in accordance with the agreement.
Phase I Study Design and Target Populations
The planned Phase I study includes dose-escalation and expansion components to evaluate the asset in biomarker-selected patient populations as an initial proof-of-concept. The study is designed to define safety, pharmacokinetics, pharmacodynamics, and early activity of the asset.
Kimia's AI-Driven Discovery Platform and Investment Backing
Kimia Therapeutics is advancing small-molecule medicines using its integrated ATLAS platform, which the company describes as a transformative approach to AI-driven drug discovery. According to the announcement, the proprietary ATLAS platform combines nanogram-scale parallel synthesis, direct-to-biology screening, and machine learning.
Kimia is a portfolio company of The Column Group (TCG), a life sciences investment firm focused on building and investing in biotechnology companies from early-stage scientific innovation through clinical development and strategic transactions.
Kimia CEO Stig Hansen said the company was delighted to work with CStone to advance the clinical development of the potential first-in-class asset, which was discovered by Kimia leveraging AI and medicinal chemistry integration.
He noted that CStone's expertise in oncology clinical development will be valuable as Kimia evaluates its lead asset in Phase I proof-of-concept studies in biomarker-selected patient populations.
CStone's Development Track Record and Strategic Rationale
The collaboration pairs CStone's oncology clinical development and regulatory expertise across multiple markets with Kimia's AI-enabled drug discovery approach. CStone's track record includes four approved innovative drugs and 21 new drug application approvals across nine indications.
Dr. Jason Yang, Chief Executive Officer, President of R&D, and Executive Director of CStone, said the company is pleased to collaborate with Kimia to advance the innovative, first-in-class oncology asset.
He described the collaboration as establishing a scalable framework with the potential to support additional programs with Kimia and other TCG portfolio companies, connecting promising innovation with a clear path to efficient and robust clinical development.
He added that the deal structure aligns the parties' shared commitment to the asset's development and long-term success while providing CStone with the opportunity to participate in the value it creates globally. Yang characterized the repeatable model as an important avenue to broaden CStone's participation in global innovation and create long-term value for its shareholders.
Framework for Future Extensions
Beyond the current asset, the collaboration establishes a scalable framework that may be extended to other promising assets over time.
According to the announcement, this creates a repeatable model for CStone to contribute its clinical development expertise to advancing innovative therapies, generate value through milestone payments and royalties, and expand its international development footprint.
Tracked in the database
Clinical Collaboration & Licensing · Asia-Pacific
Clinical Collaboration & Licensing
Asia-Pacific
Chemical
4 November 2026
3 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.